Results 121 to 130 of about 3,479,769 (339)

Systematic profiling of cancer‐fibroblast interactions reveals drug combinations in ovarian cancer

Molecular Oncology, EarlyView.
Fibroblasts, cells in the tumor environment, support ovarian cancer cell growth and alter morphology and drug response. We used fibroblast and cancer cell co‐culture models to test 528 drugs and discovered new drugs for combination treatment. We showed that adding Vorinostat or Birinapant to standard chemotherapy may improve drug response, suggesting ...
Greta Gudoityte, Osheen Sharma, Laura Leuenberger, Emelie Wallin, Josefin Fernebro, Päivi Östling, Rebecka Bergström, Johan Lindberg, Ulrika Joneborg, Olli Kallioniemi, Brinton Seashore‐Ludlow   +10 more
wiley   +1 more source

Promising Response to Neoadjuvant Chemotherapy Plus Immunotherapy in Metaplastic Breast Carcinoma

Breast Cancer: Targets and Therapy
Qingjian Tan,* Na Li,* Yan Wang, Tian Du, Gehao Liang, Zixuan Zhao, Jun Tang, Hao Wu Department of Breast Cancer, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen ...
Tan Q, Li N, Wang Y, Du T, Liang G, Zhao Z, Tang J, Wu H   +7 more
doaj  

A giant phyllodes tumor of the breast

Rare Tumors, 2016
Phyllodes tumors of the breast are rare, accounting for less than 1% of the breast tumors. They are mostly seen in women between 45 and 49 years old.
Charlotte Schillebeeckx, Guy Verbeeck, Geert Daenen, Dirk Servaes, Marc Bronckaers   +4 more
doaj   +1 more source

Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody. [PDF]

, 2019
Breast cancers enduring treatment with chemotherapy may be enriched for cancer stem cells or tumor-initiating cells, which have an enhanced capacity for self-renewal, tumor initiation, and/or metastasis.
Carson, Dennis A, Cui, Bing, Ghia, Emanuela M, He, Jinsong, Huang, Jiajia, Jiang, Wenqi, Kipps, Thomas J, Lam, Sharon, Lei, Yang, Messer, Karen, Parker, Barbara A, Schwab, Richard, Widhopf, George F, Wu, Liufeng, Yu, Jian, Zhang, Han, Zhang, Jianchao, Zhang, Suping   +17 more
core   +1 more source

Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab

Molecular Oncology, EarlyView.
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton, Russell W. Madison, Candice Francheska B. Tambaoan, Funda Meric‐Bernstam, Christopher J. Sweeney, Razelle Kurzrock, Howard A. Burris III, David R. Spigel, Hanna Tukachinsky, Jason Hughes, Julia Malato, Bongin Yoo, Tania Szado, Cheryl Schwab, Lincoln W. Pasquina, Amaya Gasco, Katja Schulze, Claire F. Friedman   +17 more
wiley   +1 more source

Adenomyoepithelioma of the breast

Hematology/Oncology and Stem Cell Therapy, 2009
Hematol Oncol Stem Cell Ther 2(2) Second Quarter 2009 hemoncstem.edmgr.com 364 Myoepithelial cells are usually present between the epithelial cells and the basal lamina of the secretory elements of the mammary duct system of the breast.1 Tumors derived from these cells are found in the skin, lungs, salivary glands and breast.
Dipti Rani Samanta, Surenra Nath Senapati, Praveen Sharma, Asit Mohanty   +3 more
openaire   +3 more sources

European-History TextsHistory of Europe--Ancient and Medieval. James H. Robinson , James H. BreastedHistory of Europe--Our Own Times. James H. Robinson , Charles A. Beard [PDF]

, 1921

openalex   +1 more source

Dose‐dependent induction of epithelial‐mesenchymal transition in 3D melanoma models by non‐thermal plasma treatment

Molecular Oncology, EarlyView.
Non‐thermal plasma treatment of melanoma cells induced epithelial‐mesenchymal transition (EMT) in a dose‐dependent fashion. This report highlights the critical need to further investigate potential adverse effects of non‐thermal plasma for cancer therapy and to optimize treatment parameters for clinical translation. Despite the promising results of non‐
Eline Biscop, Edgar Cardenas De La Hoz, Hanne Verswyvel, Joey De Backer, Ho Wa Lau, Angela Privat‐Maldonado, Wim Vanden Berghe, Steve Vanlanduit, Evelien Smits, Annemie Bogaerts, Abraham Lin   +10 more
wiley   +1 more source

Molecular imaging predicts trastuzumab‐deruxtecan (T‐DXd) response in head and neck cancer xenograft models

Molecular Oncology, EarlyView.
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed, Lucas Mani, Muhammad Bilal Mirza, Ashtyn McAdoo, Takahito Kondo, Hidenori Tanaka, Nicole Meeks, Eben Rosenthal, Marisa Hom   +8 more
wiley   +1 more source

Breast Cavernous Hemangioma with Increased Size on Ultrasonography: A Case Report

대한영상의학회지, 2018
Cavernous hemangioma of the breast is a rare benign vascular tumor. It is usually diagnosed as non-palpable mass during imaging examination, incidentally.
Kwang-Min Kim, Ji-Young Kim, Soung Hee Kim, Myeong Ja Jeong, Soo Hyun Kim, Jae Hyung Kim, Kyung Eun Bae, Ji Hae Lee, Mi-Jin Kang, Tae Gyu Kim   +9 more
doaj   +1 more source